On the other hand, increased IL‐6 levels had been associated with early hematoma growth in humans,31 and, accordingly, the reduction in this systemic inflammatory marker observed after CM352 treatment may be the result of the diminished bleeding but also a consequence of MMP inhibition. Here, IL6 is linked to hematoma.